Building a Knowledge-Product Growth Strategy for a Pharmaceutical Marketing Pioneer.

About the Client

Founded in 1990, Company A built a digital marketing and communications practice devoted exclusively to the pharmaceutical and broader healthcare industry, at a time when few agencies specialized in the sector. By 2001, Company A counted eight of the world’s 10 largest pharmaceutical companies among its clients and had built its reputation on both direct-to-consumer and direct-to-physician communications. Company A would later be acquired by a larger marketing holding company.

Industry Context

The early 2000s marked an inflection point in pharmaceutical marketing. The FDA’s 1997 guidance easing restrictions on broadcast direct-to-consumer advertising had unleashed a wave of DTC ad spending, while a rapidly growing share of consumers and physicians were turning to the internet for health information for the first time. That shift created real demand for digital expertise among pharma marketers, but it also drew new entrants into a still-young interactive marketing category, as established agency networks and independent boutiques alike raced to build healthcare specialization. Success depended less on any single campaign than on accumulated knowledge of a heavily regulated, relationship-driven industry — meaning a firm’s real asset was often the market and customer knowledge built over years of pharma-only engagements, not just its creative production capacity.

Current Situation

Despite a decade of profitable growth and a blue-chip roster, Company A had reached a revenue plateau, and rising costs had begun compressing margins. The firm had recently introduced two knowledge-based offerings and wanted to build on that early momentum, but internal attempts to generate additional offerings had failed to produce options management found credible. Company A’s president turned to Iknow for its consulting capability in business strategy, market research, and competitive intelligence, paired with deep expertise in knowledge management and the pharmaceutical industry.

• Revenue plateau despite profitability. Core services had reached a growth ceiling, and rising costs were beginning to erode margin even though the underlying business remained profitable.
• Internal ideation had stalled. Multiple in-house attempts to identify new offerings hadn’t produced a slate of options leadership trusted enough to act on.
• No clear boundary on acceptable risk. Leadership hadn’t yet defined which new offerings fit Company A’s competencies, brand, and risk tolerance versus which represented too large a departure from its core business.
• Untapped intellectual capital. Company A held deep accumulated expertise in pharmaceutical marketing, regulatory-aware communications, and its own client base, but no structured way to turn that expertise into standalone, sellable knowledge products.

• Identify a broad slate of potential new product and service offerings that build on Company A’s core competencies and existing client base.
• Establish evaluation criteria to compare and prioritize opportunities against leadership’s risk profile and strategic goals.
• Ground opportunity identification in external research — industry trends, competitor positioning, and thought-leader input — alongside a rigorous internal capability assessment.
• Deliver opportunity descriptions detailed enough to support leadership decision-making and outside fundraising.

How Iknow Structured the Work

Iknow ran the engagement as parallel internal and external workstreams — an internal capability and risk-appetite assessment alongside external market and competitive research — culminating in a structured evaluation and prioritization phase, reflecting Iknow’s growth-strategy and knowledge-monetization methodology for validating new offerings grounded in a client’s existing competencies.

Key Activities & Decisions

• Executive workshops. Iknow facilitated a series of interviews and workshops with Company A’s executive team to surface business needs, capture ideas for new offerings, and calibrate leadership’s appetite for risk.
• Capability assessment. Iknow conducted an internal assessment identifying Company A’s core skills and competencies, grounding the search for new offerings in genuine organizational strengths rather than speculative diversification.
• Evaluation framework. In parallel, Iknow developed structured criteria for comparing and prioritizing candidate opportunities across strategic fit, market potential, and execution risk.
• External research and competitive intelligence. Iknow studied pharmaceutical marketing industry trends, interviewed thought leaders in the space, and researched Company A’s competitors, mapping how peer agencies and emerging digital health platforms were building adjacent revenue streams.
• Opportunity generation. Iknow identified 31 potential new offerings, spanning synthesized industry content in text and video formats, a knowledge management portal and software toolset for the pharmaceutical marketing niche, online education centers embeddable in client websites, data mining and market research services, and a distance-learning platform.
• Prioritization workshops. Iknow facilitated a further round of workshops with the executive team to prioritize the 31 candidates, narrowing the list to the three opportunities leadership committed to pursuing.
• Business case refinement. For the three selected, Iknow refined the concepts and developed detailed cost estimates to support Company A’s business cases and conversations with outside funders.

Stakeholders & Collaboration

Iknow served as prime contractor, working directly with Company A’s president and executive leadership team as the primary sponsors and decision-makers throughout the engagement, with no subcontractors involved.

Turning Internal Ambition Into Options Leadership Actually Trusted

Company A’s president wanted new growth ideas but had already seen internal efforts fail to produce a credible slate of options, meaning any new attempt risked the same fate if it felt like more of the same thinking. Iknow addressed this by pairing a rigorous internal capability assessment with independent external research into industry trends and competitors, giving leadership an outside, evidence-grounded perspective the firm hadn’t been able to generate on its own.

Balancing Breadth of Ideation With a Focused, Fundable Shortlist

Generating dozens of plausible new offerings risked leaving Company A with the same problem in a different form: too many options and no clear path to action. Iknow addressed this by developing structured evaluation criteria up front and running dedicated prioritization workshops with the executive team, narrowing 31 candidate opportunities down to three that leadership could commit real resources and outside funding to.

Quantitative Outcomes

• Opportunities identified: 31 potential new knowledge-based product and service offerings generated and evaluated.
• Opportunities selected: Three priority offerings fully embraced by Company A’s executive team for implementation.
• Engagement duration: Five-month assignment.

Qualitative Outcomes

Company A’s executive team fully embraced the three prioritized opportunities and used Iknow’s detailed descriptions to seek outside funding to bring them to market — evidence the engagement produced decisions, not just a report. Just as important, the assignment gave Company A leadership its first structured framework for evaluating growth opportunities against its own competencies and risk tolerance, a capability the firm could reapply as the landscape continued to evolve. Company A went on to become one of pharma’s most prominent digital marketing agencies, later acquired by a larger marketing holding company and absorbed into a major healthcare-focused communications network.

Timeline to Impact

Within the five-month engagement, Company A’s executive team had already prioritized and committed to three opportunities and begun pursuing outside funding using Iknow’s business cases — giving the firm an immediate path from strategy to execution rather than a shelved report.

Core Skills

• Growth strategy & market assessment
• Competitive intelligence
• Knowledge monetization & productization
• Executive workshop facilitation

Methods & Frameworks

• Structured opportunity evaluation and prioritization criteria
• Capability-based diversification analysis
• Thought-leader and competitor research

Technologies & Tools

• Primary and secondary market and competitive research methods